Although both propofol tenofovir and entecavir are antiviral drugs for the treatment of chronic hepatitis B, which can inhibit viral replication and improve liver damage, they have many differences in terms of the time of listing, drug resistance and specific efficacy. 1. Time on the market: entecavir was listed in the United States in 2005, which is a longer time on the market, while propofol tenofovir was listed in 2018, which is a new type of antiviral drug. 2. Resistance rate: compared with entecavir, propofol tenofovir has a higher resistance barrier, lower resistance rate, and resistance is less likely to occur with long-term use. 3. Efficacy: from the point of view of metabolic pathway, entecavir is mainly excreted through the kidneys, the risk of nephrotoxicity is relatively high, while propoxyphene tenofovir mainly acts in the liver, reducing the concentration of the drug in the peripheral blood, thus reducing the risk of nephrotoxicity to a certain extent. It should be noted that propoxyphene tenofovir can be used without dose adjustment in patients with renal abnormalities who are undergoing hemodialysis, but there is no recommended dosage for patients who are not undergoing hemodialysis due to insufficient research data. Please follow your doctor’s instructions for specific dosage. During the period of medication, patients should strictly follow the doctor’s arrangement, do not take medication on their own, and prohibit the consumption of alcohol, so as to avoid unnecessary damage to the liver.